Lucid DiagnosticsLUCD -6.04%20 Debt-to-Equity is 6.70 as of Mar. 2026, which is 653% above its 10-year median of 0.89. GuruFocus rates LUCD with a GF Score™ of 20/100 and a GF Value™ of $0.82 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 98.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lucid Diagnostics's Debt-to-Equity or its related term are showing as below:
LUCD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -6.6 Med: 0.89 Max: 6.7
Current: 6.7
During the past 7 years, the highest Debt-to-Equity Ratio of Lucid Diagnostics was 6.70. The lowest was -6.60. And the median was 0.89.
LUCD's Debt-to-Equity is ranked worse than 98.86% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs LUCD: 6.70
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lucid Diagnostics Debt-to-Equity Related Terms
Lucid Diagnostics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUCD vs QTRX, INFU, APYX: Debt-to-Equity Comparison
For the Medical Devices subindustry, Lucid Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a Debt-to-Equity of 6.70 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lucid Diagnostics and its competitors. This is 653% above median its historical median of 0.89. According to the industry distribution chart, Lucid Diagnostics ranks #696 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 98.9%.
Is Lucid Diagnostics' Debt-to-Equity too high?
Lucid Diagnostics' current Debt-to-Equity of 6.70 is 653% above median its 10-year median of 0.89. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Lucid Diagnostics' value of 6.70 is 2877.8% above this industry median. Based on the distribution chart, Lucid Diagnostics ranks #696 out of 704 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Debt-to-Equity compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #696 out of 704 companies for Debt-to-Equity. This places Lucid Diagnostics in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Lucid Diagnostics' value of 6.70 is 2877.8% above this benchmark. While the company's 10-year median is 0.89 vs. the industry median of 0.23, Lucid Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current Debt-to-Equity of 6.70 is 2877.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Debt-to-Equity is 6.70, which is 653% above median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $0.97 — trading 18% above its estimated fair value. The current Debt-to-Equity is 6.70, which is 653% above median its 10-year median of 0.89 and 2877.8% above the Medical Devices & Instruments industry median of 0.23. Lucid Diagnostics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Debt-to-Equity is 6.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $0.97 is trading 18% above its estimated GF Value™ of $0.82.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
Debt-to-Equity: 6.70 (653% above median its 10-year median of 0.89)
GF Value™: $0.82 vs. price of $0.97 (18% above fair value)
Industry Position: 2877.8% above the Medical Devices & Instruments median (#696 of 704)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score
Get the complete analysis for LUCD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
